Short answer
ADC Therapeutics SA (ADCT) filed an 8-K current report with the SEC on August 13, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Q2 and first-half 2026 financial results announced for periods ended June 30, 2026.
ADC Therapeutics SA 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 and first-half 2026 financial results announced for periods ended June 30, 2026
- Full financial details and management commentary contained in Exhibit 99.1
- Results update provides investors with the latest operating performance and financial-condition data
Item 7.01 · Regulation FD Disclosure
- Investor presentation released August 13, 2026 under Regulation FD
- Exhibit 99.2 contains the substantive company update for investors
Item EX-99.1 · Exhibit EX-99.1
- Q2 product revenue $18.6M, up from $18.1M; growth driven by higher pricing rather than underlying volume
- FDA raised substantial LOTIS-5 benefit-risk concerns tied to Grade 5 events and marginal benefit, delaying the full-approval path
- LOTIS-7 enrollment completed at 100 patients, supporting potential ZYNLONTA-glofitamab expansion into 2L+ DLBCL
- Workforce reduction approximately 17%, targeting annualized cost savings of approximately $10M after trial completions
- Cash $219.1M at June 30, 2026, with runway expected into at least 2028; Q2 net loss $16.6M or $0.11 per share
Item EX-99.2 · Exhibit EX-99.2
- LOTIS-5 met its primary PFS endpoint: HR 0.73, p=0.008, median PFS 6.14 vs 4.73 months
- ZYNLONTA plus rituximab delivered higher CR rates, 40% vs 27%, and stronger 24-month CR durability, 48.5% vs 16.7%
- FDA raised substantial benefit-risk concerns after Grade 5 events, weakening the case for full approval despite efficacy improvements
- Safety burden was higher with ZYNLONTA plus rituximab: Grade 5 TEAEs 2.9% vs 1.0%, serious TEAEs 49.0% vs 34.5%
- Regulatory strategy and timing remain under evaluation, leaving earlier-line expansion and potential revenue growth uncertain
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ADC Therapeutics SA 8-K filings
Get the next ADCT 8-K as it lands
Follow ADCT for push alerts, or ask the research agent what this filing means.